Abstract 196P
Background
High-grade serous ovarian carcinoma (HGSOC) remains the deadliest gynecologic malignancy, primarily due to its asymptomatic nature in the early-stages and the complex, poorly understood mechanisms driving its progression.
Methods
In this study, we employed single-cell RNA-seq analysis to delve deeper into early-stage of HGSOC, uncovering a previously underappreciated dominant infiltration and heterogeneity of regulatory T (Treg) cells.
Results
Within the HGSOC lesions, we detected CD4 regulatory T cells (Tregs) displaying diverse transcriptomic profiles indicative of their naïve, effector, proliferating, and destabilized states. The presence of Tregs was associated with an immunosuppressive tumor microenvironment, featured by CD4 Th2 cells, exhausted CD8 T cells, lacking cytotoxicity NK cells, and tumor-associated macrophages (TAMs). Cell-to-cell communication analysis predicted Treg-mediated inhibition of immune responses and reciprocal interactions with tumor cells promoting Treg activation. Trajectory analysis revealed two Treg differentiation paths, both leading to immunosuppressive FOXP3high and FOXP3+ Treg profiles. Notably, while the trajectory of FOXP3high profile converges with proliferating Tregs, the second path of cytotoxic FOXP3+ Tregs aligned with FOXP3- ex-Tregs, distinguished by an anti-tumor CXCL13+IFNG+ transcriptomic profile.
Conclusions
Therefore, despite the immunosuppressive environment, we identified the counteracting antitumor activity of Tregs, highlighting the potential of manipulating Treg cell fate as for therapeutic strategies.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
31P - Peripheral-blood Immune-predictors of pathological complete response in patients with triple-negative breast cancer undergoing neoadjuvant chemo-immunotherapy
Presenter: Celeste Santoro
Session: Poster Display session
32P - Immune T cell subsets dynamics in the early TNBC treatment setting
Presenter: Rocío Martín Lozano
Session: Poster Display session
33P - Tumor-specific CD4 Th1 responses in long-term responder melanoma patients treated with immune checkpoint inhibitors.
Presenter: Jessica Mathiot
Session: Poster Display session
34P - Linking early immunity changes to clinical outcomes in cutaneous squamous cell carcinoma following anti-programmed death cell-1 (PD-1) treatment
Presenter: Marcella Scala
Session: Poster Display session
37P - Lymphocyte Subpopulation Balances as a Blood Biomarker for Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Presenter: Mireille Langouo fontsa
Session: Poster Display session
38P - Biomarkers predictive of response to immune checkpoint inhibitor therapy in patients with metastatic melanoma
Presenter: Eliza Bob
Session: Poster Display session
39P - Analysis of the immune response patterns in localized prostate cancer
Presenter: Sara Merler
Session: Poster Display session
40P - MANIFEST: A Multiomic Profiling Platform for Immuno-Oncology Biomarker Discovery
Presenter: Zayd Tippu
Session: Poster Display session
41P - Total tumor burden and radiomics to evaluate response in dose escalation studies: Roginolisib (IOA-244), a highly selective PI3Kd inhibitor in metastatic uveal melanoma patients
Presenter: Anna Di Giacomo
Session: Poster Display session